| Literature DB >> 27485036 |
Masayuki Kaneko1, Ikuko Iwase2, Yuki Yamasaki3, Tomoko Takai1, Yan Wu4, Soshi Kanemoto1, Koji Matsuhisa1, Rie Asada1, Yasunobu Okuma5, Takeshi Watanabe3, Kazunori Imaizumi1, Yausyuki Nomura6.
Abstract
Endoplasmic reticulum (ER)-associated degradation (ERAD) is a mechanism by which unfolded proteins that accumulate in the ER are transported to the cytosol for ubiquitin-proteasome-mediated degradation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27485036 PMCID: PMC4971459 DOI: 10.1038/srep30955
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Human ubiquitin ligase genes encoding RING-finger and transmembrane domains (C3H2C3 type).
| Gene Name | Synonym | Upstream motif | Transmembrane | Protein length | |
|---|---|---|---|---|---|
| RNF130 | G1RZFP, GOLIATH, GP | −315 | UPRE | 2 | 419 |
| RNF150 | KIAA1214 | 2 | 438 | ||
| RNF149 | FLJ90504 | −2586 | ERSE-I | 1 | 400 |
| RNF133 | 1 | 376 | |||
| RNF128 | FLJ23516, GRAIL | 1 | 428 | ||
| RNF122 | FLJ12526 | 1 | 155 | ||
| RNF24 | G1L | 1 | 148 | ||
| RNF13 | RZF | 1 | 381 | ||
| RNF167 | DKFZP566H073 | 1 | 350 | ||
| ZNRF4 | nixin, RNF204, sperizin, spzn, Ssrzf1 | 1 | 429 | ||
| RNF43† | DKFZp781H0392, FLJ20315, URCC | 2 | 783 | ||
| ZNRF3† | BK747E2.3, FLJ22057, KIAA1133, RNF203 | 1 | 936 | ||
| SYVN1‡ | DER3, HRD1 | −506−2303 | ERSE-I | 6 | 617 |
| AMFR | gp78, RNF45 | 5 | 643 | ||
| RNF175§ | FLJ34190 | 5 | 328 | ||
| RNF121§ | FLJ11099 | −2372 | UPRE | 6 | 327 |
| RNF145‡ | FLJ31951 | −1258 | ERSE-II | 12 | 663 |
| RNF139‡ | HRCA1, RCA1, TRC8 | 12 | 664 | ||
| RNF103 | hkf-1, KF1 | 4 | 685 | ||
These lists are aligned with the relatedness from a multiple sequence alignment by CLUSTALW. The same gene families are grouped into the same symbol based on the TreeFam.
Human ubiquitin ligase genes encoding RING-finger and transmembrane domains (C3HC4 type).
| Gene Name | Synonym | Upstream motif | Transmembrane | Protein length | |
|---|---|---|---|---|---|
| RNF19A | DKFZp566B1346, dorfin | −428 | UPRE-r | 2 | 838 |
| RNF19B | FLJ90005 | 2 | 732 | ||
| RNF5† | G16, NG2, RING5, RMA1 | 2 | 180 | ||
| RNF185† | FLJ38628 | 2 | 192 | ||
| RNF170 | ADSA, DKFZP564A022 | −627 | UPRE | 3 | 258 |
| RNF186‡ | FLJ20225 | 2 | 227 | ||
| RNF152‡ | FLJ39176 | 1 | 203 | ||
| RNF183 | MGC4734 | 1 | 192 | ||
| RNF182‡ | MGC33993 | 2 | 247 | ||
| TRIM59§ | Mrf1, RNF104, TSBF1 | 1 | 403 | ||
| TRIM13§ | DLEU5, Leu5, RNF77 | 1 | 407 | ||
| BFAR | BAR, RNF47 | 3 | 450 | ||
| RNF180 | −4801 | ERSE-II | 1 | 592 | |
| RNFT1 | PTD016 | 5 | 435 | ||
| RNF26 | MGC2642 | 4 | 433 | ||
| CGRRF1 | CGR19, RNF197 | 1 | 332 | ||
| MUL1 | FLJ12875, GIDE, MAPL, MULAN, RNF218 | 2 | 352 | ||
| RNF217 | dJ84N20.1, MGC26996 | 1 | 542 | ||
These lists are aligned with the relatedness from a multiple sequence alignment by CLUSTALW. The same gene families are grouped into the same symbol based on the TreeFam.
Figure 1Tissue-specific distribution of transmembrane E3 ligases.
Total RNAs from 23 human or 22 mouse tissues were reverse-transcribed and measured by TaqMan-based real-time PCR assay using the delta–delta Ct method. Data are normalised to the amount of 18S ribosomal RNA; results are expressed as the fold increase compared with cDNA pools from each tissue. (a) RNF183, (b) RNF186, (c) ZNRF4, (d) RNF182, (e) RNF150, (f) RNF175.
Figure 2ER stress response of transmembrane E3 ligases (a) Expression of E3 ligases induced by ER stressor. HeLa cells were treated with thapsigargin (Tg; 1 μM) and tunicamycin (Tm; 3 μg/ml) for the time periods as indicated. Total RNAs were reverse-transcribed and measured by TaqMan-based real-time PCR assay using the delta–delta Ct method. Data are normalized to the amount of GAPDH; results are expressed as the fold increase compared with control (mean ± SD; n = 4). (b) Expression of E3 ligases induced by the overexpression of ATF6 and XBP1. pcDNA3–ATF6α (1–373 amino acid residues),–XBP1 (spliced form), or–GFP (as a control) were transfected into HeLa cells. The cells were incubated for 36 h. Data are normalized to the amount of GAPDH; results are expressed as the fold increase compared with GFP (mean ± SD; n = 3). Statistical analysis was performed with ANOVA followed by Bonferroni correction (vs. control and GFP; *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 3Characterization of candidates for ERAD E3 ligase (a) Subcellular localisation of E3 ligases. COS-1 cells stably expressing E3-V5 were subjected to immunofluorescence staining with anti-V5 and -PDI antibodies. (b) In vitro autoubiquitination assay. The E3 proteins produced by a transcription/translation system were immunoprecipitated with anti-V5 antibody, and then mixed in the reaction buffer with E1 (GST-tagged), E2 (GST-UbcH5c) and HA-ubiquitin. The reaction mixture was again immunoprecipitated with anti-V5 antibody and analysed via Western blotting using anti-ubiquitin or V5-antibodies. CS mutants defective in E3 activity were constructed by replacement of conserved coordinating Cys with Ser residues in the RING. Asterisk indicates the heavy chain of immunoglobulin. (c) E3 ligases protect against ER stress-induced cell death. Neuro-2a (N2a) cells stably expressing WT or ΔRING (ΔR) mutant of E3 ligases were transiently treated with Tm (1 μg/ml) or staurosporine (STS; 0.1 μM) and incubated for 48 h. The cells were stained with crystal violet. The eluted dye at an optical density of 590 nm was measured. Cell viability was calculated as follows: OD for assay/OD for vehicle control (0.1% dimethyl sulfoxide) well. The results are expressed as the fold increase compared with mock cells, in terms of means ± SD (three independent experiments in duplicate). Statistical analysis was performed using ANOVA followed by Bonferroni correction (vs. controls; *p < 0.05, **p < 0.01)